

Standard PREanalytical Code Version 3.0

Fay Betsou,¹ Roberto Bilbao,² Jamie Case,³ Rodrigo Chuaqui,⁴ Judith Ann Clements,⁵ Yvonne De Souza,⁶ Annemieke De Wilde,⁷ Jörg Geiger,⁸ William Grizzle,⁹ Fiorella Guadagni,¹⁰ Elaine Gunter,¹¹ Stacey Heil,¹² Michael Kiehntopf,¹³ Iren Koppandi,¹⁴ Sabine Lehmann,¹ Loes Linsen,¹⁵ Jacqueline Mackenzie-Dodds,¹⁶ Rocio Aguilar Quesada,¹⁷ Riad Tebbakha,¹⁸ Teresa Selander,¹⁹ Katheryn Shea,²⁰ Mark Sobel,²¹ Stella Somiari,²² Demetri Spyropoulos,²³ Mars Stone,²⁴ Gunnel Tybring,²⁵ Klara Valyi-Nagy,²⁶ and Lalita Wadhwa,²⁷ and the ISBER Biospecimen Science Working Group

Keywords: quality assurance, preanalytical variables, biobank, biospecimen science

QUALITY ASSURANCE in biospecimen collection, processing, and storage is the focus of International Best Practices¹ and accreditation standards.² Traceability and documentation of the preanalytical phase is part of recently recommended lists of essential biobank datasets.^{3,4} The Standard PREanalytical Code (SPREC) was first developed and published by the ISBER Biospecimen Science Working Group in 2009⁵

and was updated in 2012.⁶ The SPREC is a seven-element code corresponding to the most critical preanalytical variables of fluid and solid biospecimens. In this short communication, the SPREC version 3.0 is published. It includes more options, based on recent technological developments and on recently acquired knowledge about the critical ranges of preanalytical times, such as tissue ischemia times (Table 1, Table 2).

TABLE 1. PREANALYTICAL VARIABLES, WITH NEW ELEMENTS IN BOLD ITALIC, INCLUDED IN SPREC (7-ELEMENT LONG SPREC), VERSION SPREC 3.0, APPLIED TO FLUID SAMPLES

Type of sample	
Ascites fluid	ASC
Amniotic fluid	AMN
Bronchoalveolar lavage	BAL
Blood (whole)	BLD
(continued)	

TABLE 1. (CONTINUED)

Type of sample	
Bone marrow aspirate	BMA
Breast milk	BMK
Buccal cells	BUC
<i>Nondensity-gradient-centrifugation-separated</i> buffy coat, viable	BUF
<i>Nondensity-gradient-centrifugation-separated</i> buffy coat, nonviable	BFF
(continued)	

¹Integrated Biobank of Luxembourg, Dudelange, Luxembourg.

²Biobanco Vasco, Torre del BEC, Barakaldo-Biskaia, Spain.

³Scripps Center for Organ & Cell Transplantation, La Jolla, California.

⁴NCI/NIH, Rockville, Maryland.

⁵Australian Prostate Cancer Bioresource/Queensland University of Technology, Brisbane, Australia.

⁶University of California, San Francisco, San Francisco, California.

⁷Universitair Ziekenhuis Antwerpen, Edegem, Belgium.

⁸Interdisciplinary Bank of Biomaterials and Data Würzburg, Würzburg, Germany.

⁹University of Alabama at Birmingham, Birmingham, Alabama.

¹⁰Interinstitutional Multidisciplinary Biobank, IRCCS San Raffaele Pisana, Rome, Italy.

¹¹Specimen Solutions LLC, Tucker, Georgia.

¹²Coriell Institute for Medical Research, Camden, New Jersey.

¹³Friedrich-Schiller Universität Jena, Jena, Germany.

¹⁴Cellular Technology Limited, Shaker Heights, Ohio.

¹⁵Biobank University Hospitals Leuven, Leuven, Belgium.

¹⁶Natural History Museum, London, United Kingdom.

¹⁷Biobanco del Sistema Sanitario Publico de Andalucia, Sevilla, Spain.

¹⁸Tumorothèque de Picardie, Place Victor Pauchet, Amiens, France.

¹⁹Biospecimen Repository and Processing Lab, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Canada.

²⁰Brooks Life Sciences Systems, Indianapolis, Indiana.

²¹ASIP, Rockville, Maryland.

²²Windber Research Institute, Windber, Pennsylvania.

²³Medical University of South Carolina, Charleston, South Carolina.

²⁴Blood Systems Research Institute, San Francisco, California.

²⁵Karolinska Institutet, Stockholm, Sweden.

²⁶University of Illinois at Chicago, Chicago, Illinois.

²⁷Texas Children's Hospital, Houston, Texas.

TABLE 1. (CONTINUED)

Type of sample	
Density-gradient-centrifugation-separated mononuclear cells, viable	CEL
Fresh cells from nonblood specimen type	CEN
Cells from nonblood specimen type (e.g., ascites, amniotic), viable	CLN
Cord blood	CRD
Cerebrospinal fluid	CSF
Enriched (physicochemically) circulating tumor cells	CTC
Dried whole blood (e.g., Guthrie cards)	DWB
Nasal washing	NAS
Density-gradient-centrifugation-separated mononuclear cells, nonviable	PEL
Cells from nonblood specimen type (e.g., ascites, amniotic), nonviable	PEN
Pleural fluid	PFL
Dental pulp	PLP
Plasma, single spun	PL1
Plasma, double spun	PL2
Red blood cells	RBC
Saliva	SAL
Semen	SEM
Serum	SER
Sputum	SPT
Stool	STL
Synovial fluid	SYN
Tears	TER
24 h urine	U24
Urine, random ("spot")	URN
Urine, first morning	URM
Urine, timed	URT
Other	ZZZ
Type of primary container	
Acid citrate dextrose	ACD
Chemical additives/stabilizers	ADD
Serum tube without clot activator	CAT
Citrate phosphate dextrose	CPD
Cell Preparation Tube [®] citrate	CPT
Cell Preparation Tube heparin	CPH
Aldehyde-based stabilizer for CTCs	CSV
EDTA and gel	EDG
Physical filtration system	FIL
Glass	GLS
Lithium heparin	HEP
Hirudin	HIR
Lithium heparin and rubber plug	LHB
Lithium heparin and gel	LHG
Oragene collection container or equivalent	ORG
Stool collection container with DNA stabilizer	OMN
PAXgene [®] blood RNA ⁺	PAX
Potassium EDTA	PED
Polyethylene tube sterile	PET
S8820 protease inhibitor tablets or equivalent	PII
Protease inhibitors	PIX
Polypropylene tube sterile	PPS
PAXgene blood DNA	PXD
PAXgene bone marrow RNA	PXR
RNA Later[®]	RNL
Sodium citrate	SCI

(continued)

TABLE 1. (CONTINUED)

Type of primary container		
Nonaldehyde-based stabilizer for cell-free nucleic acids		SCK
Sodium EDTA		SED
Sodium heparin		SHP
Sodium fluoride/potassium oxalate		SPO
Serum separator tube with clot activator		SST
Tempus [®] tube		TEM
Trace elements tube		TRC
Unknown		XXX
Other		ZZZ
Precentrifugation (delay between collection and processing)		
RT	<30 min	A1
2°C–10°C	<30 min	B1
RT	<2 h	A
2°C–10°C	<2 h	B
RT	2–4 h	C
2°C–10°C	2–4 h	D
RT	4–8 h	E
2°C–10°C	4–8 h	F
RT	8–12 h	G
2°C–10°C	8–12 h	H
RT	12–24 h	I
2°C–10°C	12–24 h	J
RT	24–48 h	K
2°C–10°C	24–48 h	L
RT	>48 h	M
2°C–10°C	>48 h	N
>35°C	<2 h	O
Unknown		X
Other		Z
Centrifugation		
RT 10–15 min	<3000 g no braking	A
RT 10–15 min	<3000 g with braking	B
2°C–10°C 10–15 min	<3000 g no braking	C
2°C–10°C 10–15 min	<3000 g with braking	D
RT 10–15 min	3000–6000 g with braking	E
2°C–10°C 10–15 min	3000–6000 g with braking	F
RT 10–15 min	6000–10000 g with braking	G
2°C–10°C 10–15 min	6000–10000 g with braking	H
RT 10–15 min	>10000 g with braking	I
2°C–10°C 10–15 min	>10000 g with braking	J
RT 30 min	<1000 g no braking	M
No centrifugation		N
Unknown		X
Other		Z
Second centrifugation		
RT 10–15 min	<3000 g no braking	A
RT 10–15 min	<3000 g with braking	B
2°C–10°C 10–15 min	<3000 g no braking	C
2°C–10°C 10–15 min	<3000 g with braking	D
RT 10–15 min	3000–6000 g with braking	E
2°C–10°C 10–15 min	3000–6000 g with braking	F
RT 10–15 min	6000–10000 g with braking	G
2°C–10°C 10–15 min	6000–10000 g with braking	H
RT 10–15 min	>10000 g with braking	I
2°C–10°C 10–15 min	>10000 g with braking	J
No centrifugation		N

(continued)

TABLE 1. (CONTINUED)

<i>Second centrifugation</i>		
Unknown		X
Other		Z
<i>Postcentrifugation delay</i>		
<1 h 2°C–10°C		A
<1 h RT		B
1–2 h 2°C–10°C		C
1–2 h RT		D
2–8 h 2°C–10°C		E
2–8 h RT		F
8–24 h 2°C–10°C		G
8–24 h RT		H
24–48 h 2°C–10°C		I
24–48 h RT		J
>48 h RT		M
Not applicable		N
Unknown		X
Other		Z
<i>Long-term storage</i>		
PP tube 0.5–2 mL	(–85) to (–60)°C	A
PP tube 0.5–2 mL	(–35) to (–18)°C	B
PP tube 0.5–2 mL	<–135°C ^a	V
Cryotube ^b 1–2 mL	LN	C
Cryotube ^b 1–2 mL	(–85) to (–60)°C	D
Cryotube ^b 1–2 mL	Programmable freezing to <–135°C	E
Plastic cryo straw	LN	F
Straw	(–85) to (–60)°C	G
Straw	(–35) to (–18)°C	H
Straw	Programmable freezing to <–135°C	I
PP tube ≥5 mL	(–85) to (–60)°C	J
PP tube ≥5 mL	(–35) to (–18)°C	K
Microplate well	(–85) to (–60)°C	L
Microplate well	(–35) to (–18)°C	M
Cryotube ^b 1–2 mL	LN after temporary (–85) to (–60)°C	N
Plastic cryo straw	LN after temporary (–85) to (–60)°C	O
Paraffin block	RT or 2–10°C	P
Paraffin block	(–35) to (–18)°C	U
Bag	LN	Q
Dry technology medium	RT	R
PP tube 40–500 µL	(–85) to (–60)°C	S
PP tube 40–500 µL	(–35) to (–18)°C	T
PP tube 40–500 µL	<–135°C ^a	W
Original primary container	(–35) to (–18)°C or (–85) to (–60)°C	Y
Unknown		X
Other		Z

Codes in bold come from the LDMS. Volumes refer to container size.

^aTemperature <–135°C may correspond to LN vapor phase or to –150°C electrical freezer.

^bCryotube is defined as a tube that can be stored in LN either vapor or liquid phase.

LDMS, Laboratory Data Management System; h, hour; LN, liquid nitrogen, referring to either vapor or liquid phase (this specific information should be documented in the biobank's SOPs); min, minute; PP, polypropylene; RT, room temperature: 18°C–28°C; SOPs, standard operating procedures.

TABLE 2. PREANALYTICAL VARIABLES, WITH NEW ELEMENTS IN BOLD ITALIC, INCLUDED IN THE SPREC (7-ELEMENT LONG SPREC), VERSION SPREC 3.0, APPLIED TO SOLID SAMPLES

<i>Type of sample</i>	
Bone	BON
Fresh cells from nonblood specimen type (e.g., biopsy)	CEN
Cells from nonblood specimen type (e.g., dissociated tissue), viable	CLN
Cells from fine needle aspirate	FNA
Hair	HAR
Cells from laser capture microdissected tissue	LCM
Nails	NAL
Cells from nonblood specimen type (e.g., dissociated tissue), nonviable	PEN
Placenta	PLC
Solid tissue	TIS
Disrupted tissue, nonviable	TCM
Teeth	TTH
Other	ZZZ
<i>Type of collection</i>	
Autopsy <6 h postmortem	A06
Autopsy 6–12 h postmortem	A12
Autopsy 12–24 h postmortem	A24
Autopsy 24–48 h postmortem	A48
Autopsy 48–72 h postmortem	A72
Biopsy in culture media	BCM
Biopsy	BPS
Biopsy in normal saline or phosphate buffered saline	BSL
Biopsy in tissue low-temperature transport media	BTM
Fine needle aspirate	FNA
Puncture	PUN
Surgical excision in culture media	SCM
Surgical excision	SRG
Surgical excision in normal saline or phosphate buffered saline	SSL
Surgical excision in tissue low-temperature transport media	STM
Surgical excision in vacuum container	VAC
Swab	SWB
Other	ZZZ
<i>Warm ischemia time</i>	
<2 min	A
2–10 min	B
10–20 min	C
20–30 min	D
30–60 min	E
>60 min	F
Unknown	X
Not applicable (e.g., biopsy)	N
Other	Z
<i>Cold ischemia time</i>	
RT <2 min	A
RT 2–10 min	B
RT 10–20 min	C
RT 20–30 min	D
RT 30–60 min	E

(continued)

TABLE 2. (CONTINUED)

<i>Cold ischemia time</i>	
RT 60 min–3 h	F
RT 3 h–6 h	G
RT 6 h–12 h	H
RT >12 h	I
2°C–10°C <60 min	E4
2°C–10°C 60 min–3 h	F4
2°C–10°C 3–6 h	G4
2°C–10°C 6–12 h	H4
2°C–10°C >12 h	I4
Unknown	X
Not applicable (e.g., autopsy)	N
Other	Z
<i>Fixation/stabilization type</i>	
Nonaldehyde with acetic acid	ACA
Aldehyde based	ALD
Allprotect® tissue reagent	ALL
Alcohol based	ETH
Nonbuffered formalin	FOR
Heat stabilization	HST
Snap freezing	SNP
Nonaldehyde based without acetic acid	NAA
Neutral buffered formalin	NBF
Optimum cutting temperature medium	OCT
PAXgene tissue	PXT
RNA Later	RNL
Vacuum technology stabilization	VAC
Unknown	XXX
Other	ZZZ
<i>Fixation time</i>	
<15 min	A
15 min–1 h	B
1–4 h	C
4–8 h	D
8–24 h	E
24–48 h	F
48–72 h	G
>72 h	H
Not applicable	N
Unknown	X
Other	Z
<i>Long-term storage</i>	
PP tube 0.5–2 mL	(–85) to (–60)°C A
PP tube 0.5–2 mL	(–35) to (–18)°C B
PP tube 0.5–2 mL	<–135°C ^a V
Cryotube ^b 1–2 mL	LN C
Cryotube ^b 1–2 mL	(–85) to (–60)°C D
Cryotube ^b 1–2 mL	Programmable freezing to <–135°C E
Plastic cryo straw	LN F
Straw	(–85) to (–60)°C G
Straw	(–35) to (–18)°C H
Straw	Programmable freezing to <–135°C I
PP tube ≥5 mL	(–85) to (–60)°C J
PP tube ≥5 mL	(–35) to (–18)°C K
Microplate well	(–85) to (–60)°C L
Microplate well	(–35) to (–18)°C M
Cryotube ^b 1–2 mL	LN after temporary (–85) to (–60)°C N

(continued)

TABLE 2. (CONTINUED)

<i>Long-term storage</i>	
Straw	LN after temporary (–85) to (–60)°C O
Paraffin block	RT or 2 to 10°C P
Paraffin block	(–35) to (–18)°C U
Bag	LN Q
Dry technology medium	RT R
PP tube 40–500 µL	(–85) to (–60)°C S
PP tube 40–500 µL	(–35) to (–18)°C T
PP tube 40–500 µL	<–135°C ^a W
Original primary container	(–35) to (–18)°C or (–85) to (–60)°C Y
Unknown	X
Other	Z

Codes in bold come from the LDMS. Volumes refer to container size.

^aTemperature <–135°C may correspond to LN vapor phase or to –150°C electrical freezer.

^bCryotube is defined as a tube that can be stored in LN, either vapor or liquid phase.

LN, Liquid nitrogen refers to either vapor or liquid phase (this specific information should be documented in the biobank's SOPs); PP, polypropylene; RT, room temperature: 18°C–28°C.

Author Disclosure Statement

No competing financial interests exist.

References

- 2012 ISBER Best Practices for repositories collection, storage, retrieval, and distribution of biological materials for research international society for biological and environmental repositories. *Biopreserv Biobank* 2012;10:79–161.
- ISO/DIS 20387:2017(E) Biotechnology–Biobanking–General requirements for biobanks. <https://www.iso.org/standard/67888.html>.
- Moore HM, Kelly A, Jewell SD, et al. Biospecimen reporting for improved study quality. *Biopreserv Biobank* 2011;9:57–70.
- Roxana M-M, Loreana N, van Enckevort D, et al. Toward global biobank integration by implementation of the minimum information about biobank data sharing (MIABIS 2.0 Core). *Biopreserv Biobank* 2016;14:298–306.
- Betsou F, Lehmann S, Ashton G, et al. Standard preanalytical coding for biospecimens: Defining the sample PREanalytical code. *Cancer Epidemiol Biomarkers Prev* 2010;19:1004–1011.
- Lehmann S, Guadagni F, Moore H, et al. Standard pre-analytical coding for biospecimens: Review and implementation of the Sample PREanalytical Code (SPREC). *Biopreserv Biobank* 2012;10:366–374.

Address correspondence to:

Fay Betsou, PhD, HDR

Integrated Biobank of Luxembourg

1 rue Louis Rech

Dudelange L-3555

Luxembourg

E-mail: fay.betsou@ibbl.lu